Clinical Trials Browser

Phase 2 × Leukemia, Myeloid, Acute × daratumumab × Clear all

NCT02807558 2024-12-13

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Completed

155 enrolled 24 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03067571 2023-09-21

Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2 Terminated

7 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute